MONAL CAPITAL



Pharma & Chemical

Fortnightly Newsletter

1st December to 15th December 2019

Investment and Exit

CX Partners, Samara in talks with drugmakers for club deal with two LPs

4th Dec 2019. VCCircle

Homegrown private equity firms CX Partners and Samara Capital are scouting for investment opportunities... <u>more</u>

Merger and Acquisition

Eris Lifesciences buys anti-diabetic drug from Novartis for India market

4th Dec 2019. VCCircle

Eris Lifesciences Ltd said it has acquired the trademark for anti-diabetic drug Zomelis for \$13 million (Rs 92.9 crore) from Novartis AG for the Indian market as the drugmaker continues to explore inorganic opportunities... more

Aster DM Healthcare acquires 80 percent stake in UAE-based Premium Healthcare

10th Dec 2019. ET Health World

Aster DM Healthcare, the third largest healthcare company in India, has completed the acquisition of 80 per cent stake in UAE-based Premium Healthcare...

Archroma acquires stilbene-based OBA business from BASF in India

9th Dec 2019. Chemicals Technology

Colour and speciality chemicals provider Archroma has announced that its Archroma India unit has closed the acquisition of stilbene-based OBA (optical brightening agents) business for paper and powder detergent applications from BASF India Limited (BIL).... more

Cipla arm signing agreement to acquire remaining 40% stake in Cipla Pharma Lanka

2nd Dec 2019. Chemarc

Cipla's wholly-owned subsidiary - Cipla (EU), holding a 60% stake in Cipla Pharma Lanka, Sri Lanka, has signed an agreement with CitiHealth Imports to acquire the remaining 40% stake in Cipla Pharma Lanka.... more

Joint Venture

As Bangladesh Pharma fast picking up, Pharmexcil foresees vast potential for Indian API players to have JVs, tech tie-ups and enhance export of raw materials

2nd Dec 2019. Pharma Biz

With Bangladesh fast picking up in the pharmaceutical sector and expected to build more than 47 Pharmaceutical Parks in and around Dhaka in the coming few days to come, the Pharmaceuticals Export Promotion Council of India (Pharmexcil) is forecasting a vast potential for the Indian active pharmaceutical ingredients (API) players to grab the opportunity... more

Piramal Pharma Solutions partners with Norway firm for leukemia treatment drug

4th Dec 2019. ET Health World

Piramal Pharma Solutions on Tuesday said it will be partnering with Norway-based firm BerGenBio ASA on the development of bemcentinib for the treatment of elderly patients with relapsed Acute Myeloid Leukemia (AML)... more

Algeria woos Indian pharma to build up presence and scouts for partnerships

14th Dec 2019. Pharma Biz

The People's Democratic Republic of Algeria has made efforts to attract the attention of Indian pharma companies... more

Pharma

Zydus Cadila files NDA for Saroglitazar Magnesium

5th Dec 2019. Economic Times

Drug firm Zydus Cadila on Thursday said it has filed New Drug Application (NDA) with the Drug Controller General of India (DCGI) for Saroglitazar Mg, used in treatment of liver disease... more

Strides Pharma gets tentative nod from USFDA for pain relieving drug

4th Dec 2019. Economic Times

Drug firm Strides Pharma Science on Wednesday said it has got tentative approval from US health regulator for Diclofenac Potassium Softgel Capsules a drug used to relieve pain... more

Pharmexcil gets proposal from Guyana to collaborate with Indian pharma cos to export cancer drugs

10th Dec 2019. Pharma Biz

The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has received a proposal from Guyana to collaborate with Indian pharmaceutical companies to export cancer drugs to Guyana.... more

HEC Pharm, Biocon, Sun Pharma get FDA approval for MS drug

6th Dec 2019. Bio Spectrum

The U.S. Food and Drug Administration has approved three applications for first generics of Gilenya (fingolimod) capsules for the treatment of relapsing forms of multiple sclerosis (MS) in adult patients... more

Karnataka govt to set up 500-acre dedicated Bulk Drug Park at Yadgir to boost bulk drug manufacturing

13th Dec 2019. Pharma Biz

The Karnataka government is planning to boost its bulk drug manufacture in the state with the setting up of a 500-acre dedicated Bulk Drug Park at Yadgir in north Karnataka... more

Chemical

CAS launches Formulus in India

3rd Dec 2019. Bio Spectrum

CAS, a division of the American Chemical Society that specializes in scientific information solutions, has now launched Formulus... more

HealthCare

ET ILC members discuss possibility of integrated healthcare system in India

9th Dec 2019. Economic Times

Integrated healthcare at a macro level means managing the overall well-being of the nation by putting the consumer at the centre; it involves delivering the required level of efficient and quality care to the consumers across their lifetime by connecting diverse stakeholders across the healthcare value chain... more

Hospital

Teleradiology Solutions to add 150 hospitals by 2022; to double the number of radiologists to 200

11th Dec 2019. Pharma Biz

Teleradiology Solutions, a global pioneer in remote radiology interpretation and telehealth, is planning to add more hospitals to its kitty from 150 to 300 over the next three years ... more

Rs 513 crore sanctioned for new hospital building at IGIMS

11th Dec 2019. ET Health World

The state cabinet on Tuesday sanctioned Rs513. 21 crore for the new hospital building with 1200 beds at Indira Gandhi Institute of Medical Sciences (IGIMS)...

Mumbai set to get hi-tech proton machine for safer cancer therapy

10th Dec 2019. ET Health World

One of the world's most sophisticated forms of cancer treatment is coming to Mumbai.... more

After Ecommerce, Reliance Gears Up For Diagnostics Business

9th Dec 2019. INC 42

After shaking up the telecom sector with Jio, Reliance is now planning to do the same to the diagnostics sector.... more

Biotech

Biocon sees a sweet spot with its affordable insulin in US

5th Dec 2019. Economic Times

Biocon is planning to take its recombinant human (rh) insulin into the US market soon and has tabled an affordable price range for the diabetes drug to the US administration... more

Biocon, Mylan launch cancer drug in US market

2nd Dec 2019. Economic Times Biocon and its partner Mylan have jointly launched cancer drug Ogivri, a biosimilar to Herceptin, in the US... <u>more</u>

Bharat Biotech launches new variant of rotavirus vaccine, Rotavac 5D

3rd Dec 2019. Live Mint

Bharat Biotech International on Tuesday launched a new variant of its rotavirus vaccine, Rotavac 5D, a smaller dosage form of its earlier oral immunisation shot that can be stored at a relatively higher temperature... more

Soligenix initiates phase 1C trial of RiVax, a lyophilized ricin toxin A-chain subunit vaccine with alum-adjuvant

14th Dec 2019. Pharma Biz

Soligenix, a late-stage biopharmaceutical company focused on developing and commercialising products to treat rare diseases where there is an unmet medical need, announced that it has opened the study titled "A phase 1C, double-blind... more

Global News

Sanofi to buy US biotech firm

9th Dec 2019. Acquisition daily

France's Sanofi has agreed to buy California-headquartered biotechnology firm Synthorx in a cash deal worth around US\$2.5bn as it steps up a push in the cancer drugs field.... more

Sanofi to sell surgical product unit Seprafilm to Baxter for \$350 mn

3rd Dec 2019. Business Standard

Medical supply company Baxter International said on Monday that it had agreed to buy Sanofi's Seprafilm unit, which makes specialist surgical products, for \$350 million in cash... more

Merck inks \$2.7B acquisition deal with ArQule

10th Dec 2019. Bio Spectrum

Merck, known as MSD outside the United States and Canada, and US based ArQule, Inc. have announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire ArQule for \$20 per share in cash for an approximate total equity value of \$2.7 billion... more

KKR and GIC affiliate complete investment in Philippines-based Metro Pacific Hospitals

10th Dec 2019. Hospital Management

Investment firm KKR, and an affiliate of GIC, Singapore's sovereign wealth fund, have completed their investments in Philippines-based Metro Pacific Hospital Holdings... more

Amneal to buy generic pharmaceuticals provider AvKAR for \$340m

11th Dec 2019. Pharmaceutical

Amneal Pharmaceuticals has signed an agreement to acquire a majority stake in generic pharmaceuticals provider AvKARE for an implied enterprise value of \$340m... more

STADA to acquire Biopharma's prescription and consumer health business

3rd Dec 2019. Pharmaceutical

STADA Group, a German generic drug manufacturer, has agreed to acquire the prescription and consumer health business of Ukrainian pharmaceutical producer Biopharma for an undisclosed price... more

Pilot Chemical purchases Mexico-based Órgano Síntesis

6th Dec 2019. Chemicals Technology

US-based chemicals company Pilot Chemical has acquired Mexican firm Órgano Síntesis for an undisclosed sum... more

Corporate Action & Management

Siddharth Mittal takes over as CEO and Joint MD of Biocon

3rd Dec 2019. ET Health World

Bengaluru based biopharmaceuticals company on Tuesday announced the elevation of Siddharth Mittal as Chief Executive Officer & Joint Managing Director of the company... more

Solara appoints Bharath R Sesha as new CEO

9th Dec 2019. ET Health World Solara Active Pharma Sciences on Monday said it has appointed Bharath R Sesha as its Chief Executive Officer (CEO)... <u>more</u>

Nanavati Super Speciality Hospital appoints Manpreet Sohal as Director & COO

10th Dec 2019. ET Health World Mumbai based Nanavati Super Speciality Hospital (NSSH) has appointed Manpreet Sohal as its Director and Chief Operating Officer (COO)... more

Best Regards



Dr. Vikas Sadvilkar Head - Pharma & Healthcare Monal Capital (P) Limited Tel.: +91-22-4976 1501 | 4976 1601 | 47081900 Mobile: +91 98210 05733 | <u>Email: vikas@monalcapital.com</u> 114, The Summit business bay, W.E. Highway Metro station, Opp.PVR, Off Andheri Kurla Road, Andheri (E) , Mumbai : 400 093 India, <u>Website:</u> www.monalcapital.com Investment Banking - Debt Syndication | Corporate Finance | Bonds | Equity | Infrastructure | Real Estate | M&A | Stress Asset Solutions | Startup & VC Advisory

Disclaimer: Information gathered & material used in this document is believed to be from reliable sources. Monal Capital however does not warrant the accuracy, reasonableness and/or completeness of any information. Monal Capital and any of its officer's directors, personnel and employees, shall not liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of this material in any manner